[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proteomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proteomics":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,74,106,126,156,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100535126","reducing-heart-failure-risk-in-late-life-with-physical-activity-100535126",false,"NCT06247774","Reducing Heart Failure Risk in Late-Life With Physical Activity","Reducing Heart Failure Risk in Late-Life With Physical Activity: Impact on Cardiac Structure and Function and Proteomic Signatures","Inclusion Criteria:\n\n* Hypertension (controlled on stable medication regimen)\n* Structural heart abnormality (LVH or LA enlargement)\n* LVEF \\> 50%\n* Sedentary\n* BMI \\\u003C30\n\nExclusion Criteria:\n\n* Diabetes\n* Unable to exercise\n* Supplemental oxygen use\n* Pulmonary hypertension\n* Sleep apnea\n* Regular exercise training\n* Devices that limit ability to achieve target heart rate\n* Moderate to severe valve disease\n* Recent (within 3 months) major CV event or planned procedures (within 6 months)\n* Terminal illness, life expectancy \\\u003C6 months\n* Inability or unwillingness to comply with study requirements\n* No access to smart phone\u002Ftablet",true,"ALL","65 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn about the molecular pathways associated with the benefit of a regular exercise program in patients with high blood pressure and who don't already participate in regular exercise.\n\nThe main question it aims to answer is to identify protein signatures associated with the benefits of a cardiac rehabilitation exercise program.\n\nThe trial will enroll 42 participants, who will be randomized to a 12 week cardiac rehabilitation exercise program versus control arm and asked to participate in the following at the beginning and end of study:\n\n* Cardiopulmonary exercise test (CPET)\n* Echocardiogram\n* Physical function test\n* 6-minute walk test\n* Hand grip strength\n* Quality of life questionnaire\n* Blood draws\n\nResearchers will compare results between those who do and don't participate in the exercise program.",[27,28,29,30],"Hypertension","Exercise Training","Cardiac Rehabilitation","Proteomics","NOT_YET_RECRUITING","2026-03-10",{"date":34,"type":35},"2026-03-12","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2029-05",{"name":41,"class":42},"Brigham and Women's Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100585616","using-4d-urinary-proteomics-to-predict-and-evaluate-treatment-response-in-colorectal-cancer-100585616","NCT06904677","Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer","Predicting and Evaluating the Efficacy of Neoadjuvant Therapy in Colorectal Cancer Based on 4D Deep Urinary Proteomics Technology","Inclusion Criteria:\n\n1. Aged 18-75 years;\n2. Pathologically confirmed diagnosis of locally advanced colorectal cancer (cT3-4 and\u002For N+);\n3. Planned to undergo neoadjuvant therapy followed by surgical resection;\n4. No evidence of distant metastasis (M0) confirmed by imaging (CT and\u002For PET-CT);\n5. Clinically assessed as being able to tolerate and complete the full course of neoadjuvant treatment;\n6. No prior anti-tumor therapy (e.g., targeted therapy, immunotherapy) before the initiation of treatment;\n7. Willing and able to provide urine samples as required;\n8. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. History of or concurrent diagnosis with other malignancies;\n2. Presence of severe hepatic, renal, cardiovascular, or metabolic diseases that may affect urinary protein metabolism;\n3. Recent use of medications known to affect protein metabolism (e.g., glucocorticoids, high-dose antibiotics);\n4. Urinary tract infection or other diseases known to cause abnormal urinary protein levels (e.g., nephrotic syndrome);\n5. Any other condition deemed unsuitable for enrollment by the investigators.","18 Years","75 Years",{"count":53,"type":21},400,"OBSERVATIONAL","The goal of this observational study is to learn how well urinary proteins can predict treatment response in patients with locally advanced colorectal cancer (LACC) undergoing neoadjuvant therapy. The main question it aims to answer is:\n\nCan urinary protein markers help predict and evaluate how patients with LACC respond to neoadjuvant therapy?\n\nParticipants diagnosed with LACC will provide urine samples before and after neoadjuvant therapy. These samples will be analyzed using 4D deep urinary proteomics and machine learning to identify proteins linked to treatment response. Some participants' tumor tissues will also be used to create organoid models for further testing.",[57,58,30],"Colorectal Cancer (CRC)","Neoadjuvant Therapy",[60,61,62],"Colorectal caner","Neoadjuvant therapy","Urinary proteomics","RECRUITING","2025-11-22",{"date":66,"type":35},"2025-11-28",{"date":68,"type":35},"2025-05-01",{"date":70,"type":21},"2029-05-01",{"name":72,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100612447","epigut-epilepsy-and-gastrointestinal-microbiota-understanding-therapy-response-100612447","NCT07253701","EPIGUT: EPILEPSY AND GASTROINTESTINAL MICROBIOTA: UNDERSTANDING THERAPY RESPONSE","EpiGUT","Inclusion Criteria:\n\n* Patients: Age 2-79 years, newly diagnosed with epilepsy, treatment-naive at time of enrollment\n* Controls: Age 2-79 years\n\nExclusion Criteria:\n\n* Patients: already started ASM treatment (more then one dose), has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy\n* Controls: previous epilepsy diagnosis or ASM treatment, has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy","2 Years","79 Years",{"count":84,"type":21},1500,"The goal of this observational study is to learn how the bacteria in the gut and mouth (called the microbiota) are linked to different types of epilepsy and how they may affect how well seizure medicines work.\n\nResearchers want to answer two main questions:\n\nAre certain types of epilepsy linked to changes in the gut or mouth microbiota? Do the bacteria in the gut change how seizure medicines work for each person?\n\nEpilepsy is a brain condition that causes seizures. Even though there are many medicines for epilepsy, some people still have seizures or side effects. Studies in animals show that gut bacteria can raise or lower the chance of seizures. Smaller studies in people suggest the same thing, but they have been limited in size and scope.\n\nIn this study, researchers will collect biological samples from people who have newly diagnosed epilepsy and from people without epilepsy (called healthy controls). The samples will be tested to learn which bacteria are present. The researchers will then look for patterns that may explain which types of epilepsy are linked to changes in the microbiota.\n\nThe study will also look at whether the bacteria in the gut and mouth affect how well anti-seizure medicines (ASMs) work. For example, the researchers will explore if certain bacteria make medicines work better or worse.\n\nPatients will provide blood, stool and saliva samples. If collected for medical reasons, cerebrospinal fluid (CSF) - the clear liquid that surrounds the brain and spinal cord -will also be used.\n\nHealthy controls will provide stool and saliva samples only\n\nAll participants will be asked to fill an online questionnaire to share health and lifestyle information.\n\nPatients also allow researchers to confidentially access data from medical records related to diagnosis and treatment.\n\nBy comparing data from many participants across Sweden, researchers hope to understand how gut and mouth bacteria influence epilepsy and seizure control.\n\nThis research may help doctors in the future to use a person's microbiota profile to choose the best seizure medicine. The long-term goal is to improve seizure control, reduce side effects, and raise the quality of life for people living with epilepsy.",[87,88,30,89,90],"Epilepsy","Microbiota","Metabolomics","Biomarker Discovery",[92,93,94,95,96],"seizures","microbiome","anti-seizure medication","gut-brain-axis","epilepsy","2025-11-19",{"date":66,"type":35},{"date":100,"type":35},"2024-02-27",{"date":102,"type":21},"2028-03",{"name":104,"class":42},"Karolinska Institutet",6,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":18,"enrollmentInfo":112,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":73},"100568345","cohort-based-study-of-diagnostic-biomarkers-for-neurosyphilis-100568345","NCT06680011","Cohort-Based Study of Diagnostic Biomarkers for Neurosyphilis","Inclusion Criteria:\n\n* Neurosyphilis Patients\n\n  1. Meet the diagnostic criteria for neurosyphilis in this study based on the 2015 Sexually Transmitted Diseases Treatment Guidelines published by the Centers for Disease Control and Prevention (CDC) and the 2020 European Guideline on the Management of Syphilis: ① Positive serological tests for Treponema pallidum (e.g., Treponemal tests) and rapid plasma reagin (RPR) tests; ② Positive cerebrospinal fluid tests for Treponema pallidum particle agglutination assay (TPPA), the toluidine red unheated serum test (TRUST), and the Venereal Disease Research Laboratory test (VDRL).\n  2. Aged 18-65 years, regardless of gender (female patients are rare in clinical practice).\n  3. At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.\n  4. No contraindications for electroencephalogram (EEG) and transcranial magnetic stimulation (TMS).\n* Non-neurosyphilis Syphilis Patients\n\n  1. Positive serological tests for Treponema pallidum (e.g., Treponemal tests) and rapid plasma reagin (RPR) tests.\n  2. Does not meet the diagnostic criteria for neurosyphilis in this study, based on the 2015 Sexually Transmitted Diseases Treatment Guidelines published by the Centers for Disease Control and Prevention (CDC) and the 2020 European Guideline on the Management of Syphilis: ① Positive serological tests for Treponema pallidum and rapid plasma reagin tests; ② Positive cerebrospinal fluid tests for Treponema pallidum particle agglutination assay (TPPA), the toluidine red unheated serum test (TRUST), and the Venereal Disease Research Laboratory test (VDRL).\n  3. Aged 18-65 years, regardless of gender (female patients are rare in clinical practice).\n  4. At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.\n  5. No contraindications for electroencephalogram (EEG).\n* Healthy Controls\n\n  1. Physically healthy (no mental illnesses or diseases affecting bodily organs).\n  2. Aged 18-65 years, regardless of gender.\n  3. At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.\n  4. No contraindications for electroencephalogram (EEG).\n\nExclusion Criteria:\n\n* Neurosyphilis Patients \\& Non-neurosyphilis Syphilis Patients\n\n  1. Age \\\u003C 18 years or \\> 65 years;\n  2. Pregnant or breastfeeding women (female patients are rare in clinical practice);\n  3. HIV-positive;\n  4. Presence of severe primary diseases (such as liver, kidney, endocrine, or hematological diseases) accompanied by autoimmune diseases or connective tissue diseases;\n  5. Presence of other central nervous system diseases besides neurosyphilis;\n  6. Contraindications for transcranial magnetic stimulation (TMS) treatment, such as history of head trauma, epilepsy, or presence of metal implants;\n  7. Contraindications for electroencephalography (EEG), such as severe scalp injuries, extensive or open cranial trauma, inability to place electrodes, or potential for infection from the examination.\n  8. Education level below junior high school.\n* Healthy Controls\n\n  1. Age \\\u003C 18 years or \\> 65 years;\n  2. Pregnant or breastfeeding women;\n  3. HIV-positive;\n  4. Other central nervous system diseases, severe physical illnesses, or major organ diseases;\n  5. Presence of severe primary diseases (such as liver, kidney, endocrine, or hematological diseases) accompanied by autoimmune diseases or connective tissue diseases;\n  6. Contraindications for electroencephalography (EEG), such as severe scalp injuries, extensive or open cranial trauma, inability to place electrodes, or potential for infection from the examination;\n  7. Education level below junior high school.",{"count":113,"type":21},360,"The goal of this observational study is to identify diagnostic biomarkers for neurosyphilis in patients with the condition. The main questions it aims to answer are:\n\nWhat plasma biomarkers are associated with neurosyphilis? What electrophysiological characteristics (EEG and eye movement) are linked to neurosyphilis? Researchers will compare biomarker data from plasma and gut microbiome analyses with electrophysiological findings to see if these factors can help diagnose neurosyphilis.\n\nParticipants will:\n\nProvide clinical information such as age, gender, symptoms, and disease course Submit blood and urine samples for proteomics and metagenomic sequencing Undergo EEG and eye movement evaluations for electrophysiological analysis",[116,117,30],"Neurosyphilis","Biomarkers","2024-11-07",{"date":120,"type":35},"2024-11-08",{"date":122,"type":35},"2024-04-01",{"date":37,"type":21},{"name":125,"class":42},"Shanghai Mental Health Center",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":73},"100382303","proteomic-analysis-in-paediatric-diabetes-type-1-papd-100382303","NCT04257877","Proteomic Analysis in Paediatric Diabetes Type 1 (PAPD)","Targeted Proteomic Analysis in the Plasma of Children With Diabetes Type 1 and Its Association With Peripheral Diabetic Neuropathy","PAPD","Inclusion Criteria:\n\n1. Children with confirmed DT1 under insulin substitution therapy\n2. Age 5-10 years\n3. Good glycemic control with HbA1c ≤ 7.0%\n4. Prepubertal patients\n5. Absence of other diseases\n6. Signed informed consent of the parents or guardians of patients\n\nExclusion Criteria:\n\n1. Presence of organic cause for neuropathy\n2. Presence of other chronic disease\n3. Poor glycemic control\n\n3\\. Medication","5 Years","10 Years",{"count":137,"type":21},50,"The aim of the present study is to investigate a targeted proteomic analysis in plasma of children - of Greek origin- with type 1 diabetes (DT1) and its correlation with the electrophysiological findings that accompany diabetic peripheral neuropathy.\n\nDiabetic neuropathy is the most frequent chronic complication in adults with DT1 and rarely appears in childhood. Nevertheless, cases of acute mononeuritis have been described at the time of diagnosis of DT1. According to recent reports several biomarkers, including proteomic analysis, have been proposed for the early detection of peripheral neuropathy in children and young adults with T1DM.\n\nIn the present study the researchers will attempt to investigate the role of biomarkers with targeted proteomic analysis in the plasma of children with DT1 in combination with an electrophysiological study, which includes a nerve conduction study, to detect early diabetic peripheral neuropathy, before the appearance of clinical manifestations.",[140,30,141],"Diabetes Type 1","Diabetic Peripheral Neuropathy",[143,144,145,146],"plasma proteomics","children","diabetes type 1","nerve conduction","2024-07-29",{"date":149,"type":35},"2024-07-31",{"date":151,"type":35},"2018-11-20",{"date":153,"type":21},"2025-01-20",{"name":155,"class":42},"Aristotle University Of Thessaloniki",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":73},"100523544","research-on-potential-biomarkers-of-prediabetes-and-diabetes-based-on-maldi-tof-ms-platform-100523544","NCT06097065","Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.","Inclusion Criteria:\n\n1. Inclusion criteria for cases:\n\n   Non pregnant people: the remaining fasting serum\u002Fplasma and urine samples of prediabetes\u002Fdiabetes patients (prediabetes: IFG: FPG 6.1-6.9mmol\u002FL, Blood glucose 2h after meal\\\u003C7.8mmol\u002FL（WHO）; IGT: FPG\\\u003C7.0mmol\u002FL, Blood glucose 2h after meal 7.8-11.1mmol\u002FL（WHO）; diabetes: Typical symptoms of diabetes, FPG \\>= 7.0mmol\u002FL or 75g OGTT 2h blood glucose \\>= 11.1mmol\u002FL).\n\n   Pregnant people: the remaining fasting serum\u002Fplasma and urine samples of gestational diabetes patients (75g OGTT test FPG \\>= 5.1mmol\u002FL or 1h blood glucose \\>= 10.0mmol\u002FL or 2h blood glucose \\>= 8.5mmol\u002FL（IADPSG; ADA)).\n2. Inclusion criteria of the controls were as follows:\n\nNon pregnant people: the remaining fasting serum\u002Fplasma and urine samples of normal population for glucose tolerance test (FPG 3.9-6.1mmol\u002FL,75g OGTT test 1h blood glucose 6.7-11.1mmol\u002FL,75g OGTT test 2h blood glucose 3.6-7.8mmol\u002FL).\n\nPregnant people: the remaining fasting serum\u002Fplasma and urine samples of people who do not meet the diagnostic criteria for gestational diabetes (3.9\\\u003C=75g OGTT test FPG\\\u003C5.1mmol\u002FL,6.7 \\\u003C= 1h blood glucose\\\u003C10.0mmol\u002FL,3.6\\\u003C=2h blood glucose\\\u003C8.5mmol\u002FL).\n\n\\-\n\nExclusion Criteria:\n\nCommon exclusion criteria for cases and control were as follows: The sample volume of serum\u002Fplasma\u002Furine is less than 300ul; Improper storage of samples or repeated freezing and thawing; The serum \u002Fplasma has obvious hemolysis, lipemia or jaundice.\n\n\\-",{"count":163,"type":21},2860,"Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum\u002Fplasma and urine between non pregnant people with normal glucose tolerance test and prediabetes \u002Fdiabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.",[166,167,168,30],"Prediabetes","Diabetes Mellitus","Gestational Diabetes Mellitus","2023-10-18",{"date":171,"type":35},"2023-10-24",{"date":173,"type":35},"2022-05-20",{"date":175,"type":21},"2026-12-31",{"name":177,"class":42},"Zhujiang Hospital",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":73},"100462875","cancer-associated-muscle-mass---molecular-factors-and-exercise-mechanisms-100462875","NCT05307367","Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms","Identifying Molecular Factors Contributing to Cancer-associated Muscle Mass Loss and Providing Clinical Evidence for Exercise Mechanisms to Functionally Restore Muscle in Cancer","PANACEA","Inclusion Criteria, WP1+WP2X+WP2:\n\n* Men and women at or above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage not eligible to concurrent chemo\u002Fradiation therapy as primary treatment\n* Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2\n* Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.\n* Having a staging\u002Fbaseline CT within 4 weeks of initiation of treatment (PET\u002FCT are also allowed), or a baseline scan planned within the first week of treatment.\n* ECOG Performance Status 0-2\n* Having signed the informed consent form\n\nExclusion Criteria, WP1+WP2X+WP2:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* Local palliative radiotherapy as primary treatment\n* ECOG Performance status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures\n\nInclusion Criteria, WP3:\n\n* Men and women above the age of 18\n* Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb\u002FIV stage\n* ECOG Performance Status 0-2\n* Having signed the informed consent form.\n\nExclusion Criteria, WP3:\n\n* Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)\n* ECOG Performance Status \\> 2\n* Physical disabilities excluding physical testing\n* Inability to understand Danish\n* Inability to understand scoring systems\u002Fpatient-reported outcome measures","100 Years",{"count":188,"type":21},144,[24],"Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight. Cancer cachexia (CC) is the involuntary loss of body weight of \\>5% within 6 months and it occurs in 50-80% of patients with metastatic cancer.\n\nIt is estimated that CC is a direct cause of up to 30% of all cancer-related deaths. No treatment currently is available to prevent CC, likely because the chemical reactions that causes of this devastating phenomenon in unknown.\n\nNo treatment currently is available to prevent muscle mass loss in patients with cancer but is urgently needed as the reduced muscle mass and function is associated with impaired physical function, reduced tolerance to anticancer therapy, poor quality of life (QoL), and reduced survival. There is evidence of an interdependence between informal caregiver (e.g. spouse) and patient QoL. Thus, identifying caregiver distress and needs can potentially benefit QoL for patients with cancer cachexia. Despite the enormous impact on disease outcomes, it is not known why the loss of muscle mass and function occurs and very few studies have investigated the underlying molecular causes in humans. In particular, there is a severe lack of studies that have obtained human skeletal muscle and adipose tissue sample material. Such reference sample materials will be invaluable to obtaining in-depth molecular information about the underlying molecular causes of the involuntary but common muscle mass and fat mass loss in cancer.\n\nAt a whole body level, cancer cachexia is associated with reduced sensitivity to the hormone insulin, high levels of lipids in the blood, and inflammation. Within the skeletal muscle, the muscle mass loss is associated with elevated protein breakdown and reduced protein build-up while emerging, yet, limited data also suggest malfunction of the power plants of the cells called mitochondrions. The role of malnutrition and how it contributes to weight loss is understood only to the extent of the observed loss of appetite and the reduced food intake because of pain, nausea, candidiasis of the mouth, and breathlessness. Evidence is increasing that the environment of the intestinal system could be implicated in cancer cachexia, yet, the possible effect of cancer and the cancer treatment on the intestinal environment is not understood. Thus, large and as yet poorly understood details of this syndrome precede a later weight loss.\n\nExercise training could help restore muscle function and how the chemical reactions works in cancer. In healthy people, and patients with diabetes, cardiovascular disease, and obesity exercise potently improves health. Exercise has been thought to slow down the unwanted effects of cancer cachexia by changing the reactions mentioned above. Thus, there is a tremendous gap in our knowledge of how and if exercise can restore the cells power plants function, muscle mass, strength, and hormone sensitivity in human cachexic skeletal muscle. Tackling that problem and examining potential mechanisms, will enable us to harness the benefits of exercise for optimizing the treatment of patients with cancer.\n\nThe data will provide novel clinical knowledge on cachexia in cancer and therefore addressing a fundamental societal problem.\n\nThree specific aims will be addressed in corresponding work packages (WPs):\n\n* investigate the involvement of hormone sensitivity of insulin and measure the chemical reactions between the cells in patients with lung cancer (NSCLC) and describe the physical performance and measure amount of e.g. muscles and adipose tissue across the 1st type of cancer treatment and understand how that is related to the disease and how patients and informal caregiver feel (WP1).\n* find changes in the chemical reactions in skeletal muscle, adipose tissue (AT), and blood samples in these patients, to understand how to predict how the disease will develop (WP2).\n* measure changes of skeletal muscle tissue in response to exercise and see if it might reverse the hormone insensitivity and improve muscle signaling and function (WP3).\n\nThe investigators believe that:\n\n* the majority of patients with advanced lung cancer, at the time of diagnosis already are in a cachectic state, where they lose appetite, and have hormonal changes, and an overall altered chemical actions between the cells affecting both muscle mass and AT. The investigators propose that all this can predict how the disease will progress, and how patient- and informal caregiver fell and how they rate their quality of life.\n* lung cancer and the treatment thereof is linked with changes in the blood, the muscle tissues, and the adipose tissues, especially in patients experiencing cachexia, that could be targeted to develop new treatment.\n* exercise can restore the muscles and improve insulin sensitivity and improve the function of the cells power plants in patients with lung cancer-associated muscle problems.",[192,193,194,195,196,197,198,199,200,201,202,203,204,205,30,206,207,208],"Cachexia","Neoplasms","Exercise","Metabolism","Body Composition","Insulin Resistance","Physical Functional Performance","Quality of Life","Sarcopenia","Caregivers","Adipose Tissue","Muscle, Skeletal","Patient Reported Outcome Measures","Gastrointestinal Microbiome","Lipidomics","Epigenomics","Mitochondria","2022-05-09",{"date":211,"type":35},"2022-05-16",{"date":213,"type":35},"2022-04-01",{"date":215,"type":21},"2028-01-01",{"name":217,"class":42},"University of Copenhagen"]